Skip to main content
Top
Published in: Endocrine 3/2021

01-09-2021 | Acromegaly | Original Article

Prevalence of vertebral fractures and serum sclerostin levels in acromegaly

Authors: Meliha Melin Uygur, Dilek Dereli Yazıcı, Onur Buğdaycı, Dilek Gogas Yavuz

Published in: Endocrine | Issue 3/2021

Login to get access

Abstract

Objective

An increased prevalence of vertebral fractures (VFs) has been reported in previous studies. The aim of this study was to evaluate the association between bone mineral density (BMD), bone turnover markers, serum sclerostin levels, and vertebral fractures (VFs) in acromegaly patients. We also evaluated the effects of gonadal status, disease activity, treatment modality, age, sex, and body mass index (BMI) on skeletal endpoints.

Design

Case–control study.

Patients and measurements

Seventy acromegaly patients (M/F:36/34, mean age 45.5 ± 11.9 years) and 70 controls (M/F:31/39; mean age 45.66 ± 11.9 years) were included. VFs, BMD, calcium metabolism, markers of bone turnover, and sclerostin levels were evaluated. BMD was measured by dual-energy X-ray absorptiometry (Hologic QDR 4500). Conventional lateral radiography of the spine was performed and the Genant method was used for the assessment of fractures of T4–L5 vertebrae.

Results

The prevalence of vertebral fractures was higher in acromegalic patients as compared with the control group (72.9 vs. 20%; p < 0.001). Serum phosphate (P) levels (3.46 ± 0.59 mg/dl vs. 3.11 ± 0.44 mg/dl; p < 0.001) and b-cross laps (CTx) levels (0.47 µg/l, range 0.04–2.38 vs. 0.28 µg/l, range 0.11–0.80; p < 0.001) were significantly higher in acromegaly patients than control subjects. Serum sclerostin levels were similar between either acromegaly patients and control subjects or acromegaly patients with VF and without VF. In the means of treatment modality, VFs were more frequent in patients treated with adjuvant gamma knife radiosurgery (GKS) (p = 0.07). In the binary logistic regression analysis, the age of the acromegaly patients, the presence of hypogonadism, and GKS treatment were the factors significantly correlated with the occurrence of spinal fractures.

Conclusions

The prevalence of VFs in patients with acromegaly is higher than in control subjects. Since advanced age, the presence of hypogonadism and GKS treatment were the factors predicting VFs in acromegaly; radiological evaluations should be considered as an emerging tool especially in those patients. Although markers of bone turnover elevated in acromegaly, they were not useful for the prediction of fractures. Serum sclerostin levels showed no discrepancy between the two groups and further studies are required for assessment of sclerostin role in this form of secondary osteoporosis.
Literature
1.
go back to reference A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira et al. Acromegaly. Nat. Rev. Dis. Prim. 5(1), 20 (2019)CrossRef A. Colao, L.F.S. Grasso, A. Giustina, S. Melmed, P. Chanson, A.M. Pereira et al. Acromegaly. Nat. Rev. Dis. Prim. 5(1), 20 (2019)CrossRef
2.
go back to reference M. Cellini, E. Biamonte, M. Mazza, N. Trenti, P. Ragucci, D. Milani et al. Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: a radiographic study with Eos 2d/3d technology. Neuroendocrinology (2020) M. Cellini, E. Biamonte, M. Mazza, N. Trenti, P. Ragucci, D. Milani et al. Vertebral fractures associated with spinal sagittal imbalance and quality of life in acromegaly: a radiographic study with Eos 2d/3d technology. Neuroendocrinology (2020)
3.
go back to reference G. Mazziotti, A.G.A. Lania, E. Canalis, Management of endocrine disease: bone disorders associated with acromegaly: mechanisms and treatment. Eur. J. Endocrinol. 181(2), R45–R56 (2019)CrossRef G. Mazziotti, A.G.A. Lania, E. Canalis, Management of endocrine disease: bone disorders associated with acromegaly: mechanisms and treatment. Eur. J. Endocrinol. 181(2), R45–R56 (2019)CrossRef
4.
go back to reference A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29(5), 535–59 (2008)CrossRef A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29(5), 535–59 (2008)CrossRef
5.
go back to reference S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Min. Res. 20(10), 1837–44 (2005)CrossRef S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi, A. Fusco, L. De Marinis et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Min. Res. 20(10), 1837–44 (2005)CrossRef
6.
go back to reference G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100(2), 384–94 (2015)CrossRef G. Mazziotti, E. Biagioli, F. Maffezzoni, M. Spinello, V. Serra, R. Maroldi et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100(2), 384–94 (2015)CrossRef
7.
go back to reference G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93(12), 4649–55 (2008)CrossRef G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93(12), 4649–55 (2008)CrossRef
8.
go back to reference M. Wassenaar, N. Biermasz, N. Hamdy, M. Zillikens, J. Van Meurs, F. Rivadeneira et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164(4), 475 (2011)CrossRef M. Wassenaar, N. Biermasz, N. Hamdy, M. Zillikens, J. Van Meurs, F. Rivadeneira et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164(4), 475 (2011)CrossRef
9.
go back to reference K. Claessen, H. Kroon, A. Pereira, N. Appelman-Dijkstra, M. Verstegen, M. Kloppenburg et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J. Clin. Endocrinol. Metab. 98(12), 4808–15 (2013)CrossRef K. Claessen, H. Kroon, A. Pereira, N. Appelman-Dijkstra, M. Verstegen, M. Kloppenburg et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J. Clin. Endocrinol. Metab. 98(12), 4808–15 (2013)CrossRef
10.
go back to reference G. Mazziotti, A. Bianchi, T. Porcelli, M. Mormando, F. Maffezzoni, A. Cristiano et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98(8), 3402–10 (2013)CrossRef G. Mazziotti, A. Bianchi, T. Porcelli, M. Mormando, F. Maffezzoni, A. Cristiano et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98(8), 3402–10 (2013)CrossRef
11.
go back to reference A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, 4 (2020)CrossRef A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105, 4 (2020)CrossRef
12.
go back to reference J. Delgado-Calle, A.Y. Sato, T. Bellido, Role and mechanism of action of sclerostin in bone. Bone 96, 29–37 (2017)CrossRef J. Delgado-Calle, A.Y. Sato, T. Bellido, Role and mechanism of action of sclerostin in bone. Bone 96, 29–37 (2017)CrossRef
13.
go back to reference A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, G.J. Atkins, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10), e25900 (2011)CrossRef A.R. Wijenayaka, M. Kogawa, H.P. Lim, L.F. Bonewald, D.M. Findlay, G.J. Atkins, Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6(10), e25900 (2011)CrossRef
14.
go back to reference G. Holdsworth, S.J. Roberts, H.Z. Ke, Novel actions of sclerostin on bone. J. Mol. Endocrinol. 62(2), R167–R85 (2019)CrossRef G. Holdsworth, S.J. Roberts, H.Z. Ke, Novel actions of sclerostin on bone. J. Mol. Endocrinol. 62(2), R167–R85 (2019)CrossRef
15.
go back to reference M. McLung, A. Frauer, S. Boonen, Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 370(5), 412–20 (2014)CrossRef M. McLung, A. Frauer, S. Boonen, Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 370(5), 412–20 (2014)CrossRef
16.
go back to reference K.A. Carpenter, R.D. Ross, Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice. J. Bone Miner. Res. 35(3), 596–607 (2020)CrossRef K.A. Carpenter, R.D. Ross, Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice. J. Bone Miner. Res. 35(3), 596–607 (2020)CrossRef
17.
go back to reference H.K. Genant, C.Y. Wu, C. Van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–48 (1993)CrossRef H.K. Genant, C.Y. Wu, C. Van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–48 (1993)CrossRef
18.
go back to reference M. Madeira, L.V. Neto, C.H. Torres, L.M.C. de Mendonça, M.R. Gadelha, M.L.F. de Farias, Vertebral fracture assessment in acromegaly. J. Clin. Densitom. 16(2), 238–43 (2013)CrossRef M. Madeira, L.V. Neto, C.H. Torres, L.M.C. de Mendonça, M.R. Gadelha, M.L.F. de Farias, Vertebral fracture assessment in acromegaly. J. Clin. Densitom. 16(2), 238–43 (2013)CrossRef
19.
go back to reference A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), e937–e46 (2020)CrossRef A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M. Biller, C. Boguszewski et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), e937–e46 (2020)CrossRef
20.
go back to reference Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active acromegaly. J. Clin. Endocrinol. Metab. 105(3), 920–4 (2020)CrossRef Z. Pekkolay, F. Kılınç, N. Gozel, E. Önalan, A.K. Tuzcu, Increased serum sclerostin levels in patients with active acromegaly. J. Clin. Endocrinol. Metab. 105(3), 920–4 (2020)CrossRef
21.
go back to reference J. Halupczok-Żyła, A. Jawiarczyk-Przybyłowska, A. Zembska, M. Bolanowski (eds) Sclerostin and fracture risk assessment in acromegaly. 21st European Congress of Endocrinology (BioScientifica, 2019) J. Halupczok-Żyła, A. Jawiarczyk-Przybyłowska, A. Zembska, M. Bolanowski (eds) Sclerostin and fracture risk assessment in acromegaly. 21st European Congress of Endocrinology (BioScientifica, 2019)
22.
go back to reference B.M. Tang, G.D. Eslick, C. Nowson, C. Smith, A. Bensoussan, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588), 657–66 (2007)CrossRef B.M. Tang, G.D. Eslick, C. Nowson, C. Smith, A. Bensoussan, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370(9588), 657–66 (2007)CrossRef
23.
go back to reference S. Chiloiro, A. Giampietro, S. Frara, C. Bima, F. Donfrancesco, C.M. Fleseriu et al. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J. Clin. Endocrinol. Metab. 105(3), e100–e7 (2020)CrossRef S. Chiloiro, A. Giampietro, S. Frara, C. Bima, F. Donfrancesco, C.M. Fleseriu et al. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J. Clin. Endocrinol. Metab. 105(3), e100–e7 (2020)CrossRef
24.
go back to reference M.M. Uygur, O. Deyneli, D.G. Yavuz, Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients. Growth Horm. IGF Res. 55, 101335 (2020)CrossRef M.M. Uygur, O. Deyneli, D.G. Yavuz, Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients. Growth Horm. IGF Res. 55, 101335 (2020)CrossRef
Metadata
Title
Prevalence of vertebral fractures and serum sclerostin levels in acromegaly
Authors
Meliha Melin Uygur
Dilek Dereli Yazıcı
Onur Buğdaycı
Dilek Gogas Yavuz
Publication date
01-09-2021
Publisher
Springer US
Published in
Endocrine / Issue 3/2021
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02751-9

Other articles of this Issue 3/2021

Endocrine 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.